Astellas Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASTELLAS, and when can generic versions of ASTELLAS drugs launch?
ASTELLAS has thirty-seven approved drugs.
There are twenty-five US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are four hundred and thirty-two patent family members on ASTELLAS drugs in forty-two countries and sixty-five supplementary protection certificates in nineteen countries.
Summary for Astellas
International Patents: | 432 |
US Patents: | 25 |
Tradenames: | 21 |
Ingredients: | 16 |
NDAs: | 37 |
Patent Litigation for Astellas: | See patent lawsuits for Astellas |
Drugs and US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-002 | Nov 22, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Astellas | PROGRAF | tacrolimus | CAPSULE;ORAL | 050708-002 | Apr 8, 1994 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-001 | Mar 6, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Astellas | CRESEMBA | isavuconazonium sulfate | POWDER;INTRAVENOUS | 207501-001 | Mar 6, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | 8,183,274 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 11,273,171 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Astellas
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,683,037 | ⤷ Try a Trial |
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 8,133,879 | ⤷ Try a Trial |
Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-002 | May 18, 1995 | 5,731,296 | ⤷ Try a Trial |
Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | 6,265,536 | ⤷ Try a Trial |
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,144,872 | ⤷ Try a Trial |
Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-003 | Jul 19, 2013 | 8,551,522 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
International Patents for Astellas Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | PA02004145 | ⤷ Try a Trial |
Slovenia | 2428508 | ⤷ Try a Trial |
Eurasian Patent Organization | 033374 | ⤷ Try a Trial |
Denmark | 3318259 | ⤷ Try a Trial |
Poland | 1850880 | ⤷ Try a Trial |
China | 102905706 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Astellas Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1893196 | C20130036 00106 | Estonia | ⤷ Try a Trial | PRODUCT NAME: ENSALUTAMIID;REG NO/DATE: K(2013)4019 (LOPLIK) 25.06.2013 |
1189916 | 122011000010 | Germany | ⤷ Try a Trial | PRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906 |
1893196 | 92338 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ENZALUTAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (XTANDI); FIRST REGISTRATION DATE: 20130625 |
1893196 | C01893196/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ENZALUTAMID; REGISTRATION NO/DATE: SWISSMEDIC 63040 03.12.2013 |
1893196 | CA 2013 00065 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625 |
2428508 | CA 2020 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: GILTERITINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/19/1399 20191028 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.